Allergan to Establish R&D Presence in Cambridge, Massachusetts
- The facility, located in Kendall Square, is expected to open in 1Q2019 -
DUBLIN, Jan. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced it will establish an R&D presence in the Kendall Square section of Cambridge, Massachusetts, a hub of science, innovation and business opportunities. The site will be led by Don Frail, PhD, Senior Vice President of Research and External Scientific Innovation (RESI) and Non-Clinical and Translational Sciences.
"One of the driving sources of innovation today comes from smaller biotechnology and pharma companies. Our new, strategic presence in Kendall Square will allow us to more easily interact and engage with venture firms and start ups in the area," said David Nicholson, EVP & Chief R&D Officer. "I am confident that our new location in Cambridge, along with Don's deep expertise will accelerate the evaluation of scientific opportunities and further deliver on our Open Science model and the next wave of potentially transformational medicines."
Dr. Frail joined Allergan in 2014, relocating from Boston to the Allergan R&D center in Irvine, CA, and has led the Research, Clinical Pharmacology, Toxicology and ADME departments including the External Science & Innovation initiatives to evaluate and implement partnerships and acquisitions across Allergan's four key therapeutic areas. Don will continue to lead the Irvine team as well. Previously, Frail led the Emerging Innovations Unit at AstraZeneca, the Indications Discovery Units at Pfizer and the CNS Discovery organization at Pharmacia.
"I'm looking forward to returning to the Boston area to establish Allergan's new presence where we will continue to identify cutting-edge technologies and opportunities that deliver the highest value to patients and their healthcare providers. Our Irvine site will continue to be the home of R&D and retain its long-established External Scientific Innovation and Non-Clinical Translational Sciences team. The new Cambridge group will be fully integrated with the Allergan organization, and serve as a portal to our other R&D sites in Madison NJ, San Francisco area, and globally," said Don Frail, PhD.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Manisha Narasimhan, PhD
View original content to download multimedia:http://www.prnewswire.com/news-releases/allergan-to-establish-rd-presence-in-cambridge-massachusetts-300773586.html
SOURCE Allergan plc
Company Codes: NYSE:AGN